FINANCIAL REPORT 8 EXPENDITURE a) R&D projects related expenditure Recognized in (Expressed in EUR) 2015 2014 IMPLEMENTATION PROJECT ASAQ - Fixed-dose Artesunate - Amodiaquine (Malaria) (1) 330,026 386,214 ASMQ - Fixed-dose Artesunate - Mefloquine (Malaria) (1) 248,622 698,075 NECT - Nifurtimox - Eflornithine co-administration for stage 2 (HAT) (4) 16,295 57,259 SSG & Paromomycin Combination Therapy for VL in Africa (2) 20,279 96,869 New VL treatments in Asia (3) 536,953 659,246 Paediatric Benznidazole (Chagas) - 143,790 TOTAL IMPLEMENTATION PROJECTS 1,152,176 2,041,453 DEVELOPMENT PROJECTS (PHASE IIB/III; REGISTRATION) Fexinidazole (HAT) (4) 7,447,957 5,843,148 New VL treatments for Bangladesh - 205,824 New VL treatments in Latin America 111,936 110,517 Coinfection HIV / Visceral Leishmaniasis (5) 684,752 698,094 TOTAL DEVELOPMENT PROJECTS 8,244,645 6,857,581 TRANSLATION PROJECTS (PRE-CLINICAL; PHASE I; PHASE IIA/POC) Fexinidazole (Chagas) (6) 640,021 1,212,669 Oxaborole SCYX-7158 (HAT) (7) 1,258,789 1,236,612 Combination Fexinidazole/Miltefosine (VL) (2) 1,693,469 1,252,599 Anfoleish (CL) (8) 405,377 350,718 CL Combination (9) 93,564 CpG-D35 (CL) (10) + PKDL (11) 318,472 216,251 Azoles E1224 (Chagas) - 46,892 New Combination including New Benz Regimen (Chagas) (12) 431,643 268,908 Biomarkers (Chagas) (13) 572,133 1,131,282 Paediatric HIV ("4-in-1" LPV/r based fixed-dose combination & Superbooster T. b./HIV) (14) 2,240,641 1,078,126 Nitroimidazole (VL-2098) + VL 0690 (15) 515,882 808,472 Flubendazole Macrofilaricide (Filaria) (16) 123,618 938,583 Emodepside Macrofilaricide (Filaria) (17) 1,584,830 58,828 Oxfendazole Macrofilaricide (Filaria) (18) 19,007 0 TylAMac Macrofilaricide (Filaria) (19) 323,758 0 TOTAL TRANSLATION PROJECTS 10,221,204 8,599,939 RESEARCH PROJECTS (SCREEN; HIT TO LEAD; LEAD OPTIMIZATION) Lead Optimization Consortia (20) 5,614,961 4,667,142 Screening Resources & Reference Screening Centres (21) 1,333,656 1,359,345 Screening Filaria (22) 974,272 823,924 TOTAL RESEARCH PROJECTS 7,922,889 6,850,411 Project-related variable expenditure HCV, Mycetoma, and Anti-infective 618,048 187,268 Chagas Access (23) 228,753 0 R&D Coordination & Supervision (24) 4,320,562 3,109,458 TOTAL OF PROJECTS RELATED EXPENDITURE 32,708,277 27,646,111 82 › DNDi Annual Report 2015
FINANCIAL REPORT MAIN R&D PARTNERS & SUB-CONTRACTORS: Partners and service providers with financial compensation above EUR 5,000 in 2015 are: (1) SITEC, India / Bertin Pharma, France / AEDES, Belgium / Centre Hospitalier Universitaire Vaudois (CHUV), Switzerland / VENN Life Sciences, France / Mahidol Oxford, Thailand / National Institute of Medical Research, Tanzania (2) Kenya Medical Research Institute, Kenya / Amudat Hospital, Uganda / Uppsala University, Sweden / Biomedic, France / MSF Logistique, France / UBC United Biosource, Switzerland / Institute of Endemic Diseases (IEND) and University of Khartoum, Sudan / IDA Solution, the Netherlands / Organisation for Social Science Research in Eastern and Southern Africa (OSSREA), and Addis Abeba University, Ethiopia / Arba Minch Hospital, Ethiopia / Makerere University, Uganda / MDL Srl, Italy / i+solutions, the Netherlands (3) Rajendra Memorial Research Institute of Medical Sciences (RMRI), India / GVK Biosciences, India (4) Swiss TPH, Switzerland / PNLTHA, DRC / INRB Kinshasa, DRC / Jeffery travels, DRC / La Référence Médicale, DRC / UBC United Biosource, Switzerland / Biotrial, UK / Institute of Tropical Medicine- Antwerp, Belgium / SGS, Belgium and France / VENN life Science, France / Vanga CBCO Clinic, DRC / RCTS, France / Phinc Development, France / Cardiabase, France / MSF-Logistique, France and Switzerland / Aptuit, UK / Scinopsis, France / Bertin Pharma, France / Theradis Pharma, France / Biomedic, France / Sanofi Aventis, France / Sunnikan, France / PNLTHA, Chad (5) Gondar University, Ethiopia / LSHTM, UK / UBC United Biosource, Switzerland / Institut Tropical Medicine (ITM), Belgium / NLADF Research Foundation, the Netherlands / Appledown, UK / Uppsala University, Sweden (6) CEADES, Bolivia / JSS, Canada / Phinc, France / UBC United Biosource, Switzerland / Cardiabase, France (7) AVISTA (SCYNEXIS), USA / Patheon, UK / Eurofins Optimed, France / SGS, Belgium & France / Voisin consulting, France / Phinc, France / Cardiabase, France (8) PECET Universidade de Antioquia, Colombia / JSS, Canada / CECIF, Colombia / Allianz, Brazil (9) Universidad Peruana Cayetano Heredia, Peru (10) Genedesign, Japan / Ohio University, USA (11) ICDDRB, Bangladesh / Hospital Universitario de Fuenlabrada (FCSAI), Spain (12) Fundacion Instituto De Biologica Y Medicinal, Argentina / Núcleo de Desenvolvimento Farmacêutico e Cosmético (NUDFAC), Brazil / Phinc, France / LAT Reasearch, Argentina / (13) Texas Biomedical Research Institute, USA / McGill University, Canada / University of Georgia, USA / Barcelona Center for International Health Research (CRESIB), Spain (14) CIPLA, India / University of Stellenbosch, South Africa / Kenya Paediatric Research Consortium, Kenya / WuXi AppTech, China / Associated Medical Sciences, Thailand / Joint Clinical Research Centre, Uganda / Kenya Medical Research Institute, Kenya / Baylor College of Medecine, USA / Kotak, India / Epicentre, France / Gertude Hospital Foundation, Kenya / Biomedic, France (15) Aptuit, UK / Bsys, Switzerland / Advinus, India / Diane Creasy, USA (16) Juniper Pharma, UK / Swansea Innovations, UK / Wuxi App Tec, China (17) Hammersmith Medicine, UK / Bayer, Germany / UBC United Biosource, Switzerland / Creapharm, France / Syngene, India / MC Toxicology Consul, Austria (18) Wuxi App Tec, China (19) Abbvie, USA / Wuxi App Tec, China (20) Epichem Pty Ltd, Australia / Syngene, India / CEMSA Laboratory, Brazil / WuXi AppTech, China / Monash University, Australia / TCG Life Science Ltd, India / Advinus, India / London School of Hygiene & Tropical Medecine LSHTM, UK / Griffith University, Australia / Antwerp University, Belgium / Centro Nacional de Energia em Energia e Materiels (CNPEM), Brazil / Sandexis, UK / Accelera, Italy / Wil Research, France / Advinus, India / CEREP, France / Selvita, Poland / Pharmaterials Limited, UK / Sara Pharm, Romania / Eurofins, France (21) Swiss TPH, Switzerland / University of Antwerp, Belgium / GlaxoSmithKline (GSK-Tres Cantos), Spain / IPK, South Korea / Exquiron, Switzerland / Dundee University, UK / Bio ascent, UK (22) Northwick Park Institute for Medical Research (NPIMR), UK / National Museum of Natural History, France / University Hospital of Bonn, Germany / WuXi AppTec, China / University of Bari, Italy / CEA LETI, France / REFOTDE, Cameroon (23) Elea, Argentina / ISGlobal Barcelona Institut for Global Health, Spain (24) R&D Coordination & Supervision: Sunnikan, UK / VOLT Europe Limited: UK / M Benton, UK Breakdown of R&D coordination expenditure per activities (Expressed in EUR) 2015 2014 Coordination 2,379,164 1,790,898 Scientific Advisory 130,771 94,713 Committee Business Development 1,220,343 847,990 Japan Representation 453,506 255,461 Office Medical, Access and Medical Coordination Latin America 136,779 120,396 TOTAL 4,320,562 3,109,458 CONSULTANTS AND PROJECT STAFF INVOLVED IN R&D PROJECTS: Latin America office: Rodrigues, Belaine; De Jesus, Teresinha; Pinheiro, Eloan; Garcia, Facundo; Gonçalves, Luciana; Caicedo, Andres; Mechali, Daniel (in memoriam); Valencia, Carlos; Marchiol, Andrea; Zicker, Fabio; Barbeitas, Mady; Bernal, Oscar; Marques, Tayná; Boni, Marina; Christmann, Leandro; Dessoy, Marco; Martinez, Pablo; De Oliveira, Celso; Noya, Oscar; Barp, Cristiane; Certo, Marina India office: Sharma, Bhawna DRC office: Dinanga Muzadi, Joses; Kabangu Mundidimbi, Patrice; Ngolo Tete, Digas; Kande, Victor; Ciebue Bilumbu, Laurent; Diyi Lobo, Michel; Cimanga Kabongo, Dieudonne; Kabulu, Jean-Albert; Solo, Monique; Kabangu, Gabriel; Maki, Baudouin; Babingwa, Delon; Lenvo, Dally; Tsaku, Justin; Malenge, Lazare; Konga, Raymond; Pambala, Odette DNDi Annual Report 2015 › 83
Change language